Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents

被引：636

作者：

Bartlett, JB

Dredge, K

Dalgleish, AG

机构：

[1] Celgene Corp, Warren, NJ 07059 USA

[2] St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England

来源：

NATURE REVIEWS CANCER | 2004年 / 4卷 / 04期

关键词：

D O I：

10.1038/nrc1323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for multiple myeloma. A series of immunomodulatory drugs - created by chemical modification of thalidomide - have been developed to overcome the original devastating side effects. Their powerful anticancer properties mean that these drugs are now emerging from thalidomide's shadow as useful anticancer agents.

引用

页码：314 / 322

页数：10

共 57 条

[1]

ATRA E, 1993, CLIN EXP RHEUMATOL, V11, P487

[2] Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers [J].

Bartlett, JB ;

Michael, A ;

Clarke, IA ;

Dredge, K ;

Nicholson, S ;

Kristeleit, H ;

Polychronis, A ;

Pandha, H ;

Muller, GW ;

Stirling, DI ;

Zeldis, J ;

Dalgleish, AG .

BRITISH JOURNAL OF CANCER, 2004, 90 (05) :955-961

[3] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[4] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[5] Thalidomide inhibits tumor necrosis factor-α production and antigen presentation by Langerhans cells [J].

Deng, L ;

Ding, WH ;

Granstein, RD .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (05) :1060-1065

[6] Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects [J].

Dredge, K ;

Marriott, JB ;

Macdonald, CD ;

Man, HW ;

Chen, R ;

Muller, GW ;

Stirling, D ;

Dalgleish, AG .

BRITISH JOURNAL OF CANCER, 2002, 87 (10) :1166-1172

[7] Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity [J].

Dredge, K ;

Marriott, JB ;

Todryk, SM ;

Muller, GW ;

Chen, R ;

Stirling, DI ;

Dalgleish, AG .

JOURNAL OF IMMUNOLOGY, 2002, 168 (10) :4914-4919

[8] Taming TNF: strategies to restrain this proinflammatory cytokine [J].

Eigler, A ;

Sinha, B ;

Hartmann, G ;

Endres, S .

IMMUNOLOGY TODAY, 1997, 18 (10) :487-492

[9] Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].

Eisen, T ;

Boshoff, C ;

Mak, I ;

Sapunar, F ;

Vaughan, MM ;

Pyle, L ;

Johnston, SRD ;

Ahern, R ;

Smith, IE ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817

[10] Thalidomide: a new anticancer drug? [J].

Fanelli, M ;

Sarmiento, R ;

Gattuso, D ;

Carillio, G ;

Capaccetti, B ;

Vacca, A ;

Roccaro, AM ;

Gasparini, G .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (07) :1211-1225

← 1 2 3 4 5 6 →